Yu HH, et al. - Authors in the present article delineated their experience in the management of Goblet cell carcinomas (GCCs) with peritoneal carcinomatosis (PC) through cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). They, in addition, determined the impact of multiple clinical characteristics on the prognosis. They identified management of GCC with PC as challenging. CRS and HIPEC, followed by adjuvant systemic chemotherapy, seemed a promising strategy to improve survival. This appeared especially effective in selected patients with low peritoneal cancer index (PCI) and possibility to achieve complete cytoreduction.

Methods

• Authors collected the data of 15 patients with GCC and PC from a prospectively maintained database of patients receiving CRS and HIPEC for peritoneal surface malignancy.
• They performed neoadjuvant laparoscopic HIPEC if indicated.
• They performed CRS and HIPEC with mitomycin-C or 5-fluorouracil plus oxaliplatin.
• If suitable for the patient’s condition, adjuvant chemotherapy was also arranged.

Results

• The enrolled patients comprised of nine males and six females; mean age was 52.4 years.
• After the diagnosis of GCC with PC and after definitive CRS–HIPEC, the estimated median survival was 28 and 17 months, respectively.
• In this study, the 1-, 2-, 3-, 4-year survival rates were 86%, 69%, 57%, and 24%, respectively.
• As per Log-rank test, the relevant independent risk factors for more favorable outcomes were age >50 years, peritoneal cancer index (PCI) <27, postoperative PCI <20, administration of HIPEC, and adjuvant chemotherapy.
• In multivariate analyses, it was confirmed that administration of HIPEC played a crucial role in providing prognostic benefit.